Specifications
- Purity
- ≥99% (HPLC)
- Appearance
- White to light yellow crystalline powder
- Identity
- 1H-NMR
Properties
- Solvents
- Soluble in DMF (20 mg/ml), DMSO (20 mg/ml) or ethanol (20 mg/ml). Insoluble in water.
- Melting Point
- 77-78 °C (lit.)
Available from stock
Mitotane
- SKU
- D0724
Category: Other Pollutants
- Synonyms
- 2,4'-DDD, o,p?-DDD, 2,4'-Dichlorodiphenyl)dichloroethane, o,p?-TDE, CB 313, NSC 38721, Opeprim
- 53-19-0
- CAS-Number
- C14H10Cl4
- Molecular Formula
- 320.04
- Molecular Weight
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
- Shipping
- AMBIENT
- Short Term Storage
- +4°C
- Long Term Storage
- +4°C
- Handling Advice
- Protect from light and moisture.
- Use / Stability
- Stable for at least 2 years after receipt when stored at +4°C.
- Hazard statements
- H351
- Precautionary statements
- P201 - P202 - P280 - P308 + P313 - P405 - P501
- GHS Symbol
- GHS08
- Signal word
- Warning
- Transportation
- Not dangerous goods
- Description
- Mitotane (o,p’DDD) is an adrenocorticolytic agent primarily used in research related to adrenal gland disorders, especially adrenocortical carcinoma (ACC). Mitotane is an inhibitor of steroidogenesis and mitochondrial complex IV, also known as cytochrome c oxidase, activity in H295R cells. It selectively targets adrenal cortex cells by disrupting mitochondrial function and steroidogenesis, leading to cytotoxic and endocrine-suppressive effects. Mitotane is a selective inhibitor of sterol-Oacyl-transferase 1 (SOAT1), also known as ACAT1, (acyl-coenzyme A cholesterol acyltransferase). Mitotane inhibits enzymes involved in cortisol synthesis, such as CYP11A1 and CYP11B1, and induces adrenal atrophy. Mitotane acts through mitochondrial toxicity (induction of apoptosis), inhibition of cell proliferation in ACC, inhibition of steroidogenic enzymes, and selective adrenal cytotoxicity, making it effective in treating adrenocortical carcinoma and Cushing’s syndrome. Compound can be used as analytical reference material.
- Smiles
- C(C(Cl)Cl)(C1=C(Cl)C=CC=C1)C2=CC=C(Cl)C=C2
- InChi Key
- JWBOIMRXGHLCPP-UHFFFAOYSA-N
- References
- (1) S. Hahner & M. Fassnacht, Curr. Opin. Investig. Drugs 6, 386 (2005) , (2) S. De Francia, et al., Minerva Endocrinol. 37, 9 (2012) , (3) S. Hescot, et al., Endocr. Relat. Cancer 20, 371 (2013) , (4) U. Waszut, et al., J. Physiol. Pharmacol. 68, 13 (2017) , (5) M. Lo Iacono, et al., Cancers 13, 5255 (2021)
- InChi
- InChI=1S/C14H10Cl4/c15-10-7-5-9(6-8-10)13(14(17)18)11-3-1-2-4-12(11)16/h1-8,13-14H
Mitotane (o,p’DDD) is an adrenocorticolytic agent primarily used in research related to adrenal gland disorders, especially adrenocortical carcinoma (ACC). Mitotane is an inhibitor of steroidogenesis and mitochondrial complex IV, also known as cytochrome c oxidase, activity in H295R cells. It selectively targets adrenal cortex cells by disrupting mitochondrial function and steroidogenesis, leading to cytotoxic and endocrine-suppressive effects. Mitotane is a selective inhibitor of sterol-Oacyl-transferase 1 (SOAT1), also known as ACAT1, (acyl-coenzyme A cholesterol acyltransferase). Mitotane inhibits enzymes involved in cortisol synthesis, such as CYP11A1 and CYP11B1, and induces adrenal atrophy. Mitotane acts through mitochondrial toxicity (induction of apoptosis), inhibition of cell proliferation in ACC, inhibition of steroidogenic enzymes, and selective adrenal cytotoxicity, making it effective in treating adrenocortical carcinoma and Cushing’s syndrome. Compound can be used as analytical reference material.
Additional information
| Synonyms | 2,4'-DDD, o,p?-DDD, 2,4'-Dichlorodiphenyl)dichloroethane, o,p?-TDE, CB 313, NSC 38721, Opeprim |
|---|---|
| Purity | ≥99% (HPLC) |
| Appearance | White to light yellow crystalline powder |
| CAS-Number | 53-19-0 |
| Molecular Formula | C14H10Cl4 |
| Molecular Weight | 320.04 |
| Identity | 1H-NMR |
| Solvents | Soluble in DMF (20 mg/ml), DMSO (20 mg/ml) or ethanol (20 mg/ml). Insoluble in water. |
| Melting Point | 77-78 °C (lit.) |
| Smiles | C(C(Cl)Cl)(C1=C(Cl)C=CC=C1)C2=CC=C(Cl)C=C2 |
| InChi Key | JWBOIMRXGHLCPP-UHFFFAOYSA-N |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | +4°C |
| Handling Advice | Protect from light and moisture. |
| Use / Stability | Stable for at least 2 years after receipt when stored at +4°C. |
| Hazard statements | H351 |
| Precautionary statements | P201 – P202 – P280 – P308 + P313 – P405 – P501 |
| GHS Symbol | GHS08 |
| Signal word | Warning |
| Transportation | Not dangerous goods |
| References | (1) S. Hahner & M. Fassnacht, Curr. Opin. Investig. Drugs 6, 386 (2005), (2) S. De Francia, et al., Minerva Endocrinol. 37, 9 (2012), (3) S. Hescot, et al., Endocr. Relat. Cancer 20, 371 (2013), (4) U. Waszut, et al., J. Physiol. Pharmacol. 68, 13 (2017), (5) M. Lo Iacono, et al., Cancers 13, 5255 (2021) |
| InChi | InChI=1S/C14H10Cl4/c15-10-7-5-9(6-8-10)13(14(17)18)11-3-1-2-4-12(11)16/h1-8,13-14H |
| Quantity | 250 mg, Bulk |
